Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives $30.67 Consensus Price Target from Analysts

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have earned a consensus recommendation of “Hold” from the nine brokerages that are covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $30.6667.

A number of equities analysts recently weighed in on LKFT shares. Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. TD Cowen started coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They set a “buy” rating on the stock. Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Finally, Morgan Stanley decreased their target price on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 11th.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of LKFT opened at $26.81 on Friday. The firm has a market cap of $1.77 billion, a P/E ratio of -19.01 and a beta of 0.28. Lakefront Biotherapeutics American Depositary Shares has a 12-month low of $25.68 and a 12-month high of $37.78. The company’s 50-day moving average price is $28.46 and its 200 day moving average price is $29.18.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.97) by $1.01. The company had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $7.29 million. Equities research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -1.27 earnings per share for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Several hedge funds have recently made changes to their positions in LKFT. Western Standard LLC acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the fourth quarter valued at approximately $1,046,000. UBS Group AG lifted its holdings in Lakefront Biotherapeutics American Depositary Shares by 128.4% during the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after buying an additional 196,445 shares in the last quarter. Jump Financial LLC purchased a new position in Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter valued at approximately $692,000. Aquatic Capital Management LLC boosted its position in Lakefront Biotherapeutics American Depositary Shares by 63.6% in the 3rd quarter. Aquatic Capital Management LLC now owns 17,516 shares of the biotechnology company’s stock valued at $607,000 after buying an additional 6,807 shares during the period. Finally, National Bank of Canada FI acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter worth $494,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.